{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T09:07:21Z","timestamp":1789549641974,"version":"build-2803163510"},"reference-count":268,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T00:00:00Z","timestamp":1789516800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pharmacol."],"abstract":"<jats:p>G protein-coupled receptors are among the largest protein superfamilies in the human genome and are responsible for sensing diverse extracellular signals and mediating them into cellular responses. Owing to their broad range of subunits and downstream effectors regulated by specific ligands, these receptors have been appealing pharmacological targets for the discovery of new drugs. Peptide agonists emerged as compelling treatment options for metabolic disorders, and many are currently used in therapy. This perspective comprehensively summarizes the medicinal chemistry efforts over the past 5\u00a0years toward the discovery of novel agonists targeting G protein-coupled receptors as promising, life-changing peptide therapies to treat metabolic disorders, like obesity and diabetes.<\/jats:p>","DOI":"10.3389\/fphar.2026.1930768","type":"journal-article","created":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T08:35:47Z","timestamp":1789547747000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Peptide-based therapeutics targeting GPCRs: recent applications in the treatment of metabolic disorders"],"prefix":"10.3389","volume":"17","author":[{"given":"Simona","family":"Di Martino","sequence":"first","affiliation":[{"name":"Ri.MED Foundation","place":["Palermo, Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"De Rosa","sequence":"additional","affiliation":[{"name":"Ri.MED Foundation","place":["Palermo, Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,9,16]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1080\/08998280.2025.2456441","article-title":"Efficacy and safety of retatrutide, a novel GLP-1, GIP, and glucagon receptor agonist for obesity treatment: a systematic review and meta-analysis of randomized controlled trials","volume":"38","author":"Abdrabou Abouelmagd","year":"2025","journal-title":"Proc. (Bayl. Univ. Med. Cent.)"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.7554\/eLife.12977","article-title":"Time-resolved studies define the nature of toxic IAPP intermediates, providing insight for anti-amyloidosis therapeutics","volume":"5","author":"Abedini","year":"2016","journal-title":"Elife"},{"key":"B3","doi-asserted-by":"publisher","first-page":"6275","DOI":"10.1016\/S0021-9258(17)37366-0","article-title":"Structure-activity studies of glucagon-like peptide-1","volume":"269","author":"Adelhorst","year":"1994","journal-title":"J. Biol. Chem."},{"key":"B4","doi-asserted-by":"publisher","first-page":"987","DOI":"10.1016\/j.cmet.2019.07.013","article-title":"Glucose-dependent insulinotropic polypeptide receptor-expressing cells in the hypothalamus regulate food intake","volume":"30","author":"Adriaenssens","year":"2019","journal-title":"Cell Metab."},{"key":"B5","doi-asserted-by":"publisher","first-page":"e164921","DOI":"10.1172\/jci.insight.164921","article-title":"Hypothalamic and brainstem glucose-dependent insulinotropic polypeptide receptor neurons employ distinct mechanisms to affect feeding","volume":"8","author":"Adriaenssens","year":"2023","journal-title":"JCI Insight"},{"key":"B6","doi-asserted-by":"publisher","first-page":"18365","DOI":"10.1074\/jbc.M710466200","article-title":"Targeted ablation of glucose-dependent insulinotropic polypeptide-producing cells in transgenic mice reduces obesity and insulin resistance induced by a high fat diet","volume":"283","author":"Althage","year":"2008","journal-title":"J. Biol. Chem."},{"key":"B7","doi-asserted-by":"publisher","first-page":"2607","DOI":"10.1016\/S0140-6736(18)30726-8","article-title":"MEDI0382, a GLP-1 and glucagon receptor dual agonist, in obese or overweight patients with type 2 diabetes: a randomised, controlled, double-blind, ascending dose and phase 2a study","volume":"391","author":"Ambery","year":"2018","journal-title":"Lancet"},{"key":"B8","doi-asserted-by":"publisher","first-page":"101282","DOI":"10.1016\/j.molmet.2021.101282","article-title":"KBP-066A, a long-acting dual amylin and calcitonin receptor agonist, induces weight loss and improves glycemic control in obese and diabetic rats","volume":"53","author":"Andreassen","year":"2021","journal-title":"Mol. Metab."},{"key":"B9","doi-asserted-by":"publisher","first-page":"447","DOI":"10.1038\/s41574-024-00979-9","article-title":"Targeting the incretin system in obesity and type 2 diabetes mellitus","volume":"20","author":"Ansari","year":"2024","journal-title":"Nat. Rev. Endocrinol."},{"key":"B10","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1021\/acsptsci.8b00051","article-title":"Identification of key structural motifs involved in 7 transmembrane signaling of adhesion GPCRs","volume":"2","author":"Arimont","year":"2019","journal-title":"ACS Pharmacol. Transl. Sci."},{"key":"B11","doi-asserted-by":"publisher","first-page":"649","DOI":"10.1016\/s2213-8587(26)00126-9","article-title":"Efficacy and safety of once-weekly cagrilintide-semaglutide (CagriSema) in adults with type 2 diabetes inadequately controlled on diet and exercise (REIMAGINE 1): a randomised, double-blind, placebo-controlled, phase 3a study","volume":"14","author":"Aroda","year":"2026","journal-title":"Lancet Diabetes Endocrinol."},{"key":"B12","doi-asserted-by":"publisher","first-page":"25513","DOI":"10.1021\/jacs.4c05297","article-title":"Converting the amyloidogenic islet amyloid polypeptide into a potent nonaggregating peptide ligand by side chain-to-side chain macrocyclization","volume":"146","author":"Babych","year":"2024","journal-title":"J. Am. Chem. Soc."},{"key":"B13","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1038\/s41586-020-2545-9","article-title":"Lysosome-targeting chimaeras for degradation of extracellular proteins","volume":"584","author":"Banik","year":"2020","journal-title":"Nature"},{"key":"B14","doi-asserted-by":"publisher","first-page":"2622","DOI":"10.1111\/febs.15800","article-title":"Metabolic roles of G protein-coupled receptor signaling in obesity and type 2 diabetes","volume":"288","author":"Barella","year":"2021","journal-title":"FEBS J"},{"key":"B15","doi-asserted-by":"publisher","first-page":"2317","DOI":"10.1111\/dom.70427","article-title":"GLP-1R biased cAMP agonism maintains glycemic control with reduced malaise and emesis in preclinical mammalian models","volume":"28","author":"Baumer-Harrison","year":"2026","journal-title":"Diabetes Obes. Metab."},{"key":"B16","doi-asserted-by":"publisher","first-page":"577","DOI":"10.1021\/acsmedchemlett.8b00226","article-title":"Chemical strategies for half-life extension of biopharmaceuticals: Lipidation and its alternatives","volume":"9","author":"Bech","year":"2018","journal-title":"ACS Med. Chem. Lett."},{"key":"B17","doi-asserted-by":"publisher","first-page":"3256","DOI":"10.1039\/D1SC06844J","article-title":"An integrated platform approach enables discovery of potent, selective and ligand-competitive cyclic peptides targeting the GIP receptor","volume":"13","author":"Bhushan","year":"2022","journal-title":"Chem. Sci."},{"key":"B18","doi-asserted-by":"publisher","first-page":"1340","DOI":"10.1021\/acschembio.0c00308","article-title":"Hydrocarbon-stitched peptide agonists of glucagon-like Peptide-1 receptor","volume":"15","author":"Bird","year":"2020","journal-title":"ACS Chem. Biol."},{"key":"B19","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1080\/08998280.2006.11928181","article-title":"Exenatide (Byetta) as a novel treatment option for type 2 diabetes mellitus","volume":"19","author":"Bond","year":"2006","journal-title":"Proc. (Bayl. Univ. Med. Cent.)"},{"key":"B20","doi-asserted-by":"publisher","first-page":"501214","DOI":"10.1101\/2022.07.23.501214","article-title":"EvoBind: in silico directed evolution of peptide binders with AlphaFold","volume":"2022","author":"Bryant","year":"2022","journal-title":"bioRxiv"},{"key":"B21","doi-asserted-by":"publisher","first-page":"1105","DOI":"10.1038\/s41589-020-0589-7","article-title":"Structural insights into probe-dependent positive allosterism of the GLP-1 receptor","volume":"16","author":"Bueno","year":"2020","journal-title":"Nat. Chem. Biol."},{"key":"B22","doi-asserted-by":"publisher","first-page":"4860","DOI":"10.1021\/acs.biochem.7b00492","article-title":"Glucagon-like peptide 1 conjugated to recombinant human serum albumin variants with modified neonatal Fc receptor binding properties. Impact on molecular structure and half-life","volume":"56","author":"Bukrinski","year":"2017","journal-title":"Biochem."},{"key":"B23","doi-asserted-by":"publisher","first-page":"662","DOI":"10.1016\/s2213-8587(26)00125-7","article-title":"Cagrilintide-semaglutide (CagriSema) versus semaglutide or cagrilintide in people with type 2 diabetes (REIMAGINE 2): a double-blind, randomised, controlled, phase 3 study","volume":"14","author":"Buse","year":"2026","journal-title":"Lancet Diabetes Endocrinol."},{"key":"B24","doi-asserted-by":"publisher","first-page":"1673","DOI":"10.1111\/dom.70006","article-title":"Efficacy and safety of CT-868, a novel, fully biased, dual glucagon-like peptide-1\/glucose-dependent insulinotropic polypeptide receptor agonist, in type 2 diabetes: a double-blind, randomized placebo controlled phase 2 trial","volume":"28","author":"Chakravarthy","year":"2026","journal-title":"Diabetes Obes. Metab."},{"key":"B25","doi-asserted-by":"publisher","first-page":"1014","DOI":"10.1021\/acs.bioconjchem.3c00120","article-title":"Glycosylation improves the proteolytic stability of exenatide","volume":"34","author":"Chandrashekar","year":"2023","journal-title":"Bioconjugate Chem."},{"key":"B26","doi-asserted-by":"publisher","first-page":"7276","DOI":"10.1021\/acs.jmedchem.4c00093","article-title":"Engineering of a biologically active glycosylated glucagon-like Peptide-1 analogue","volume":"67","author":"Chandrashekar","year":"2024","journal-title":"J. Med. Chem."},{"key":"B27","doi-asserted-by":"publisher","first-page":"3685","DOI":"10.1021\/acs.jmedchem.1c01456","article-title":"The design and optimization of monomeric multitarget peptides for the treatment of multifactorial diseases","volume":"65","author":"Chen","year":"2022","journal-title":"J. Med. Chem."},{"key":"B28","doi-asserted-by":"publisher","first-page":"106808","DOI":"10.1016\/j.bioorg.2023.106808","article-title":"Evolution of peptide YY analogs for the management of type 2 diabetes and obesity","volume":"140","author":"Chen","year":"2023","journal-title":"Bioorg. Chem."},{"key":"B29","doi-asserted-by":"publisher","first-page":"291","DOI":"10.3390\/biom15020291","article-title":"G-Protein-Coupled receptor (GPCR) signaling and pharmacology in metabolism: physiology, mechanisms, and therapeutic potential","volume":"15","author":"Cho","year":"2025","journal-title":"Biomolecules"},{"key":"B30","doi-asserted-by":"publisher","first-page":"447","DOI":"10.1038\/s41366-019-0386-0","article-title":"Long-acting CCK analogue NN9056 lowers food intake and body weight in obese G\u00f6ttingen Minipigs","volume":"44","author":"Christoffersen","year":"2020","journal-title":"Int. J. Obes."},{"key":"B31","volume-title":"A Safety Study of LY3437943 Given as a Single Injection in Healthy Participants","year":"2019"},{"key":"B32","volume-title":"ALT-801 in Diabetic and Non-diabetic Overweight and Obese Subjects with Non-alcoholic Fatty Liver Disease (NAFLD)","year":""},{"key":"B33","volume-title":"Efficacy and Safety of ALT-801 in the Treatment of Obesity","year":""},{"key":"B34","volume-title":"Extension of ALT-801 in Diabetic and Non-diabetic Overweight and Obese Subjects with (NAFLD)","year":""},{"key":"B35","volume-title":"ALT-801 (Pemvidutide) in Healthy Overweight and Obese Volunteers to Study Safety and Tolerability","year":""},{"key":"B36","volume-title":"Efficacy and Safety of Maridebart Cafraglutide in Adult Participants with Type 2 Diabetes Mellitus Who Have Obesity or Are Overweight (MARITIME-2)","year":""},{"key":"B37","volume-title":"Evaluation of Maridebart Cafraglutide in Adult Participants Without Type 2 Diabetes Mellitus Who Have Obesity or Are Overweight","year":""},{"key":"B38","volume-title":"Pemvidutide (ALT-801) DDI Study in Healthy Volunteers","year":""},{"key":"B39","volume-title":"A Phase 2 Study Evaluating the Co-Administration of Bremelanotide with Tirzepatide for the Treatment of Obesity (BMT-801)","year":""},{"key":"B40","volume-title":"Phase 2 Study of HEC88473 Injection in Subjects with Type 2 Diabetes Mellitus","year":""},{"key":"B41","volume-title":"A Phase 3 Study to Evaluate the Efficacy of XW003 Compared with Placebo in T2DM Patients","year":""},{"key":"B42","volume-title":"A Phase 3 Study to Evaluate the Efficacy of XW003 in Adults with Overweight or Obesity","year":""},{"key":"B43","volume-title":"A Research Study Looking at How a Single Dose of the Medicine Cagrilintide Works in Participants with Reduced Liver Function and in Healthy Participants with Normal Liver Function and How Cagrilintide is Absorbed and Used by the Body","year":""},{"key":"B44","volume-title":"A Research Study to Compare Blood Levels of Cagrilintide and Semaglutide After Combined Versus Separate Injections in People with Overweight or Obesity","year":""},{"key":"B45","volume-title":"XW004 to Evaluate the Safety, Tolerability, PK, and PD of Oral Ecnoglutide Tablet in Healthy Adults","year":""},{"key":"B46","volume-title":"Efficacy and Safety of Petrelintide in Participants with Overweight or Obesity and Type 2 Diabetes (ZUPREME 2)","year":""},{"key":"B47","volume-title":"IMPACT TRIAL: Efficacy and Safety of Pemvidutide in Subjects with Nonalcoholic Steatohepatitis (NASH) (IMPACT)","year":""},{"key":"B48","volume-title":"Investigating How Cagrisema, Semaglutide and Cagrilintide Regulate Insulin Effects in the Body of People with Type 2 Diabetes","year":""},{"key":"B49","volume-title":"Maridebart Cafraglutide in Heart Failure with Preserved or Mildly Reduced Ejection Fraction and Obesity (MARITIME-HF)","year":""},{"key":"B50","volume-title":"Maridebart Cafraglutide Versus Placebo in Adult Participants with Obstructive Sleep Apnea Not on Positive Airway Pressure (PAP) Therapy (MARITIME-OSA-2)","year":""},{"key":"B51","volume-title":"Once-Weekly Petrelintide Versus Placebo for Obesity or Overweight with Co-morbidities (ZUPREME)","year":""},{"key":"B52","volume-title":"A Research Study Looking into How Cagrilintide Influences Food Intake and Appetite in People with Overweight or Obesity","year":""},{"key":"B53","volume-title":"RESTORE TRIAL: A Phase 2 Study Evaluating the Efficacy and Safety of Pemvidutide in the Treatment of Alcohol-Associated Liver Disease (ALD) Conditions","year":""},{"key":"B54","volume-title":"A Study in People with Overweight or Obesity to Compare How 2 Different Formulations of Survodutide Are Taken up by the Body","year":""},{"key":"B55","volume-title":"A Study of Retatrutide (LY3437943) in Participants Who Have Obesity or Overweight (TRIUMPH-1)","year":""},{"key":"B56","volume-title":"A Study of Retatrutide (LY3437943) in Participants with Obesity and Cardiovascular Disease (TRIUMPH-3)","year":""},{"key":"B57","volume-title":"A Study of Retatrutide (LY3437943) in Participants with Obesity or Overweight (TRIUMPH-8)","year":""},{"key":"B58","volume-title":"A Study of Retatrutide (LY3437943) in Participants Without Type 2 Diabetes Who Have Obesity or Overweight (TRIUMPH-9)","year":""},{"key":"B59","volume-title":"A Study to Test Whether Survodutide (BI 456906) Helps Chinese People Living with Overweight or Obesity to Lose Weight","year":""},{"key":"B60","volume-title":"A Study to Test Whether Survodutide Improves How the Body Uses Energy and Breaks down Fat in People with Obesity","year":""},{"key":"B61","volume-title":"Understanding the Effect of Cagrisema, Cagrilintide, and Semaglutide on Muscle Health (Role of Amylin Signature in Muscle Health) (RASMUS)","year":""},{"key":"B62","volume-title":"Weight Loss in People Living with Overweight or Obesity and Type 2 Diabetes Following Treatment with Cagrilintide (RENEW 2)","year":""},{"key":"B63","doi-asserted-by":"publisher","first-page":"4283","DOI":"10.1021\/jm200371q","article-title":"Progress in structure based drug design for G protein-coupled receptors","volume":"54","author":"Congreve","year":"2011","journal-title":"J. Med. Chem."},{"key":"B64","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1016\/j.molmet.2018.09.009","article-title":"LY3298176, a novel dual GIP and GLP-1 receptor agonist for the treatment of type 2 diabetes mellitus: from discovery to clinical proof of concept","volume":"18","author":"Coskun","year":"2018","journal-title":"Mol. Metab."},{"key":"B65","doi-asserted-by":"publisher","first-page":"1234","DOI":"10.1016\/j.cmet.2022.07.013","article-title":"LY3437943, a novel triple glucagon, GIP, and GLP-1 receptor agonist for glycemic control and weight loss: from discovery to clinical proof of concept","volume":"34","author":"Coskun","year":"2022","journal-title":"Cell Metab."},{"key":"B66","doi-asserted-by":"publisher","first-page":"11688","DOI":"10.1021\/acs.jmedchem.4c00022","article-title":"NN1213 \u2013 a potent, long-acting, and selective analog of human Amylin","volume":"67","author":"Dahl","year":"2024","journal-title":"J. Med. Chem."},{"key":"B67","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1016\/s0140-6736(25)01185-7","article-title":"Amycretin, a novel, unimolecular GLP-1 and amylin receptor agonist administered subcutaneously: results from a phase 1b\/2a randomised controlled study","volume":"406","author":"Dahl","year":"2025","journal-title":"Lancet"},{"key":"B68","doi-asserted-by":"publisher","first-page":"4947","DOI":"10.1021\/acs.jmedchem.1c00032","article-title":"Exendin 4-Hapten conjugate capable of binding with endogenous antibodies for peptide half-life extension and exerting long-acting hypoglycemic activity","volume":"64","author":"Dai","year":"2021","journal-title":"J. Med. Chem."},{"key":"B69","doi-asserted-by":"publisher","first-page":"108045","DOI":"10.1016\/j.phrs.2025.108045","article-title":"History of glucagon-like peptide-1 receptor agonists","volume":"222","author":"Darwish","year":"2025","journal-title":"Pharmacol. Res."},{"key":"B70","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1126\/science.add2187","article-title":"Robust deep learning\u2013based protein sequence design using ProteinMPNN","volume":"378","author":"Dauparas","year":"2022","journal-title":"Science"},{"key":"B71","doi-asserted-by":"publisher","first-page":"749","DOI":"10.1038\/nchembio.209","article-title":"A new glucagon and GLP-1 co-agonist eliminates obesity in rodents","volume":"5","author":"Day","year":"2009","journal-title":"Nat. Chem. Biol."},{"key":"B72","doi-asserted-by":"publisher","first-page":"1686","DOI":"10.1021\/bi971937o","article-title":"Enhanced protein thermostability by Ala--Aib replacement","volume":"37","author":"De Filippis","year":"1998","journal-title":"Biochem."},{"key":"B73","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1007\/s001250050903","article-title":"Dipeptidyl peptidase IV resistant analogues of glucagon-like peptide-1 which have extended metabolic stability and improved biological activity","volume":"41","author":"Deacon","year":"1998","journal-title":"Diabetologia"},{"key":"B74","doi-asserted-by":"publisher","first-page":"773","DOI":"10.1016\/S0140-6736(24)01498-3","article-title":"Semaglutide and cardiovascular outcomes in patients with obesity and prevalent heart failure: a prespecified analysis of the SELECT trial","volume":"404","author":"Deanfield","year":"2024","journal-title":"Lancet"},{"key":"B75","doi-asserted-by":"publisher","first-page":"1811","DOI":"10.1016\/S0140-6736(21)02188-7","article-title":"Tirzepatide versus insulin glargine in type 2 diabetes and increased cardiovascular risk (SURPASS-4): a randomised, open-label, parallel-group, multicentre, phase 3 trial","volume":"398","author":"Del Prato","year":"2021","journal-title":"Lancet"},{"key":"B76","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1038\/s41589-023-01400-8","article-title":"Computational design and genetic incorporation of lipidation mimics in living cells","volume":"20","author":"Ding","year":"2024","journal-title":"Nat. Chem. Biol."},{"key":"B77","doi-asserted-by":"publisher","first-page":"e202410237","DOI":"10.1002\/anie.202410237","article-title":"Potent and protease resistant azapeptide agonists of the GLP-1 and GIP receptors","volume":"63","author":"Dinsmore","year":"2024","journal-title":"Angew. Chem. Int. Ed."},{"key":"B78","doi-asserted-by":"publisher","first-page":"20819","DOI":"10.1021\/jacs.5c04095","article-title":"Molecular design of unimolecular tetra-receptor agonists","volume":"147","author":"Dinsmore","year":"2025","journal-title":"J. Am. Chem. Soc."},{"key":"B79","doi-asserted-by":"publisher","first-page":"117630","DOI":"10.1016\/j.bmc.2024.117630","article-title":"Design of a novel long-acting dual GLP-1\/GIP receptor agonist","volume":"100","author":"Dong","year":"2024","journal-title":"Bioorg. Med. Chem."},{"key":"B80","doi-asserted-by":"publisher","DOI":"10.1530\/JOE-23-0226","article-title":"The GLP-1R as a model for understanding and exploiting biased agonism in next-generation medicines","volume":"261","author":"Douros","year":"2024","journal-title":"J. Endocrinol."},{"key":"B81","doi-asserted-by":"publisher","first-page":"102124","DOI":"10.1016\/j.molmet.2025.102124","article-title":"A GLP-1 analogue optimized for cAMP-biased signaling improves weight loss in obese mice","volume":"100","author":"Douros","year":"2025","journal-title":"Mol. Metab."},{"key":"B82","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1016\/S0065-7743(08)00001-8","article-title":"Chapter 1 recent advances in corticotropin-releasing factor receptor antagonists","volume":"43","author":"Dzierba","year":"2008","journal-title":"Annu. Rep. Med. Chem."},{"key":"B83","doi-asserted-by":"publisher","first-page":"104936","DOI":"10.1016\/j.jpet.2026.104936","article-title":"Arginine vasopressin: a promising therapeutic target for metabolic syndrome","volume":"393","author":"Elsamad","year":"2026","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"B84","doi-asserted-by":"publisher","first-page":"5632","DOI":"10.3390\/ijms22115632","article-title":"Principles and current clinical landscape of multispecific antibodies against cancer","volume":"22","author":"Elshiaty","year":"2021","journal-title":"Int. J. Mol. Sci."},{"key":"B85","doi-asserted-by":"publisher","first-page":"657","DOI":"10.1007\/978-3-031-63657-8_22","article-title":"Targeted nano-based systems for the anti-obesity agent's delivery","volume":"1460","author":"Engin","year":"2024","journal-title":"Adv. Exp. Med. Biol."},{"key":"B86","volume-title":"E. Peptide-drug Conjugates for Weight Loss Maintenance. European Commission. CORDIS - EU Research Results","year":"2025"},{"key":"B87","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1038\/nm.3761","article-title":"A rationally designed monomeric peptide triagonist corrects obesity and diabetes in rodents","volume":"21","author":"Finan","year":"2015","journal-title":"Nat. Med."},{"key":"B88","doi-asserted-by":"publisher","first-page":"e3147","DOI":"10.1002\/psc.3147","article-title":"Adrenomedullin disulfide bond mimetics uncover structural requirements for AM1 receptor activation","volume":"25","author":"Fischer","year":"2019","journal-title":"J. Pept. Sci."},{"key":"B89","doi-asserted-by":"publisher","first-page":"23925","DOI":"10.1021\/acs.jmedchem.5c01185","article-title":"Development of petrelintide: a potent, stable, long-acting human Amylin analogue","volume":"68","author":"Fischer Munch","year":"2025","journal-title":"J. Med. Chem."},{"key":"B90","doi-asserted-by":"publisher","first-page":"720","DOI":"10.1016\/S0140-6736(23)01163-7","article-title":"Efficacy and safety of co-administered once-weekly cagrilintide 2.4 mg with once-weekly semaglutide 2.4 mg in type 2 diabetes: a multicentre, randomised, double-blind, active-controlled, phase 2 trial","volume":"402","author":"Frias","year":"2023","journal-title":"Lancet"},{"key":"B91","doi-asserted-by":"publisher","first-page":"123845","DOI":"10.1016\/j.lfs.2025.123845","article-title":"Characterization of 0839 \u2013 a tool compound for pre-clinical mode-of-action studies of amylin analogues such as cagrilintide","volume":"378","author":"Gabery","year":"2025","journal-title":"Life Sci."},{"key":"B92","doi-asserted-by":"publisher","first-page":"1151","DOI":"10.1111\/j.1432-1033.1994.1151b.x","article-title":"Structure\/activity characterization of glucagon-like Peptide-1","volume":"225","author":"Gallwitz","year":"1994","journal-title":"Eur. J. Biochem."},{"key":"B93","doi-asserted-by":"publisher","first-page":"635","DOI":"10.1056\/NEJMoa2502081","article-title":"Coadministered cagrilintide and semaglutide in adults with overweight or obesity","volume":"393","author":"Garvey","year":"2025","journal-title":"N. Engl. J. Med."},{"key":"B94","doi-asserted-by":"publisher","first-page":"6682","DOI":"10.1039\/D3CC01140B","article-title":"Enhancing the gastrointestinal stability of salmon calcitonin through peptide stapling","volume":"59","author":"Ghareeb","year":"2023","journal-title":"Chem. Comm."},{"key":"B95","doi-asserted-by":"publisher","first-page":"1010","DOI":"10.1111\/dom.14663","article-title":"Growth differentiation factor 15 (GDF15) and semaglutide inhibit food intake and body weight through largely distinct, additive mechanisms","volume":"24","author":"Ghidewon","year":"2022","journal-title":"Diabetes Obes. Metab."},{"key":"B96","doi-asserted-by":"publisher","first-page":"482","DOI":"10.1016\/j.bbadis.2013.05.004","article-title":"Neural melanocortin receptors in obesity and related metabolic disorders","volume":"1842","author":"Girardet","year":"2014","journal-title":"Biochim. Biophys. Acta"},{"key":"B97","doi-asserted-by":"publisher","first-page":"8208","DOI":"10.1021\/acs.jmedchem.1c01856","article-title":"A small-molecule oral agonist of the human glucagon-like Peptide-1 receptor","volume":"65","author":"Griffith","year":"2022","journal-title":"J. Med. Chem."},{"key":"B98","doi-asserted-by":"publisher","first-page":"101762","DOI":"10.1016\/j.molmet.2023.101762","article-title":"Discovery of ecnoglutide - a novel, long-acting, cAMP-biased glucagon-like peptide-1 (GLP-1) analog","volume":"75","author":"Guo","year":"2023","journal-title":"Mol. Metab."},{"key":"B99","doi-asserted-by":"publisher","first-page":"E821","DOI":"10.1152\/ajpendo.00514.2015","article-title":"KBP-088, a novel DACRA with prolonged receptor activation, is superior to davalintide in terms of efficacy on body weight","volume":"310","author":"Gydesen","year":"2016","journal-title":"Am. J. Physiol. Endocrinol. Metab."},{"key":"B100","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1016\/j.bcp.2017.03.018","article-title":"Characterization of signal bias at the GLP-1 receptor induced by backbone modification of GLP-1","volume":"136","author":"Hager","year":"2017","journal-title":"Biochem. Pharmacol."},{"key":"B101","doi-asserted-by":"publisher","first-page":"e70248","DOI":"10.1002\/edm2.70248","article-title":"Comparative effectiveness of CagriSegma, semaglutide, cagrilintide and tirzepatide in the management of overweight and obesity: a network meta-analysis of randomized clinical trials","volume":"9","author":"Hamarsheh","year":"2026","journal-title":"Endocrinol. Diabetes Metab."},{"key":"B102","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1016\/j.ejps.2018.07.032","article-title":"Lipidation and conformational constraining for prolonging the effects of peptides: Xenopus glucagon-like peptide 1 analogues with potent and long-acting hypoglycemic activity","volume":"123","author":"Han","year":"","journal-title":"E. J. Pharm. Sci."},{"key":"B103","doi-asserted-by":"publisher","first-page":"8561","DOI":"10.1039\/C8SC01777H","article-title":"Zwitterlation mitigates protein bioactivity loss in vitro over PEGylation","volume":"9","author":"Han","year":"","journal-title":"Chem. Sci."},{"key":"B104","doi-asserted-by":"publisher","first-page":"2906","DOI":"10.1021\/acs.molpharmaceut.0c00995","article-title":"Stapled, long-acting xenopus GLP-1-Based dual GLP-1\/Glucagon receptor agonists with potent therapeutic efficacy for metabolic disease","volume":"18","author":"Han","year":"2021","journal-title":"Mol. Pharm."},{"key":"B105","doi-asserted-by":"publisher","first-page":"5467","DOI":"10.1080\/21655979.2022.2031418","article-title":"Novel glucagon-like peptide-1 analogue exhibits potency-driven G-protein biased agonism with promising effects on diabetes and diabetic dry eye syndrome","volume":"13","author":"Hao","year":"2022","journal-title":"Bioengineered"},{"key":"B106","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1016\/j.jhep.2024.07.006","article-title":"Effect of pemvidutide, a GLP-1\/glucagon dual receptor agonist, on MASLD: a randomized, double-blind, placebo-controlled study","volume":"82","author":"Harrison","year":"2025","journal-title":"J. Hepatol."},{"key":"B107","doi-asserted-by":"publisher","first-page":"863","DOI":"10.1016\/s2213-8587(25)00196-2","article-title":"Efficacy and safety of cAMP-biased GLP-1 receptor agonist ecnoglutide versus dulaglutide in patients with type 2 diabetes and elevated glucose concentrations on metformin monotherapy (EECOH-2): a 52-week, multicentre, open-label, non-inferiority, randomised, phase 3 trial","volume":"13","author":"He","year":"2025","journal-title":"Lancet Diabetes Endocrinol."},{"key":"B108","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1016\/j.tips.2013.11.001","article-title":"Insights into the structure of class B GPCRs","volume":"35","author":"Hollenstein","year":"2014","journal-title":"Trends Pharmacol. Sci."},{"key":"B109","doi-asserted-by":"publisher","first-page":"115","DOI":"10.7570\/jomes20098","article-title":"Oxytocin: a potential therapeutic for obesity","volume":"30","author":"Hong","year":"2021","journal-title":"J. Obes. Metab. Syndr."},{"key":"B110","doi-asserted-by":"publisher","first-page":"326","DOI":"10.4239\/wjd.v15.i3.326","article-title":"Glucagon-like-peptide-1 receptor agonists and the management of type 2 diabetes-backwards and forwards","volume":"15","author":"Horowitz","year":"2024","journal-title":"World J. Diabetes"},{"key":"B111","doi-asserted-by":"publisher","first-page":"5346","DOI":"10.1021\/acsomega.8b00467","article-title":"Glycosaminoglycan conjugation for improving the duration of therapeutic action of glucagon-like Peptide-1","volume":"3","author":"Ichikawa","year":"2018","journal-title":"ACS Omega"},{"key":"B112","doi-asserted-by":"publisher","first-page":"623","DOI":"10.1016\/S2213-8587(22)00188-7","article-title":"Efficacy and safety of tirzepatide monotherapy compared with dulaglutide in Japanese patients with type 2 diabetes (SURPASS J-mono): a double-blind, multicentre, randomised, phase 3 trial","volume":"10","author":"Inagaki","year":"2022","journal-title":"Lancet Diabetes Endocrinol"},{"key":"B113","volume-title":"Top 25 Companies in Global Peptide Therapeutics Market (2025\u20132035): Competitive Analysis and Forecast","author":"Inside","year":"2026"},{"key":"B114","doi-asserted-by":"publisher","first-page":"1570","DOI":"10.3390\/biom11111570","article-title":"The parathyroid hormone-related protein\/parathyroid hormone 1 receptor axis in adipose tissue","volume":"11","author":"Izquierdo-Lahuerta","year":"2021","journal-title":"Biomolecules"},{"key":"B115","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1002\/9781119824701.ch07","article-title":"A survey and guide to the development of fatty acid-derivatized peptide therapeutics","volume":"7","author":"Jacobsen","year":"2025","journal-title":"Peptide Sci."},{"key":"B116","doi-asserted-by":"publisher","first-page":"1532076","DOI":"10.3389\/fendo.2025.1532076","article-title":"The role of GIPR in food intake control","volume":"16","author":"James-Okoro","year":"2025","journal-title":"Front. Endocrinol. (Lausanne)"},{"key":"B117","doi-asserted-by":"publisher","first-page":"843","DOI":"10.1056\/NEJMoa2504214","article-title":"Once-monthly maridebart cafraglutide for the treatment of obesity \u2014 a phase 2 trial","volume":"393","author":"Jastreboff","year":"2025","journal-title":"N. Engl. J. Med."},{"key":"B118","doi-asserted-by":"publisher","first-page":"e143228","DOI":"10.1172\/jci.insight.143228","article-title":"Antagonizing somatostatin receptor subtype 2 and 5 reduces blood glucose in a gut- and GLP-1R\u2013dependent manner","volume":"6","author":"Jepsen","year":"2021","journal-title":"JCI Insight"},{"key":"B119","doi-asserted-by":"publisher","first-page":"777","DOI":"10.1016\/s2213-8587(25)00141-x","article-title":"Efficacy and safety of a biased GLP-1 receptor agonist ecnoglutide in adults with overweight or obesity: a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial","volume":"13","author":"Ji","year":"2025","journal-title":"Lancet Diabetes Endocrinol."},{"key":"B120","doi-asserted-by":"publisher","first-page":"180","DOI":"10.1021\/acs.jmedchem.3c01049","article-title":"Discovery of a novel glucagon-like Peptide-1 (GLP-1) analogue from bullfrog and investigation of its potential for designing GLP-1-based multiagonists","volume":"67","author":"Jiang","year":"2024","journal-title":"J. Med. Chem."},{"key":"B121","article-title":"A class of long-acting GLP-1\/GIP receptor dual agonists and their applications","author":"Jing","year":"2023","journal-title":"China Patent Application"},{"key":"B122","doi-asserted-by":"publisher","first-page":"7341","DOI":"10.1021\/acs.jmedchem.4c02970","article-title":"A new protractor potentiates glucagon-like peptide 1 with slow-release depot and long-term action","volume":"68","author":"Jing","year":"2025","journal-title":"J. Med. Chem."},{"key":"B123","doi-asserted-by":"publisher","first-page":"1805","DOI":"10.1152\/physrev.00031.2017","article-title":"The oxytocin receptor: from intracellular signaling to behavior","volume":"98","author":"Jurek","year":"2018","journal-title":"Physiol. Rev."},{"key":"B124","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1016\/j.mce.2009.06.010","article-title":"The role of gut hormones in the regulation of body weight and energy homeostasis","volume":"316","author":"Karra","year":"2010","journal-title":"Mol. Cell. Endocrinol."},{"key":"B125","doi-asserted-by":"publisher","first-page":"1339","DOI":"10.1016\/j.joca.2019.05.016","article-title":"A dual amylin and calcitonin receptor agonist inhibits pain behavior and reduces cartilage pathology in an osteoarthritis rat model","volume":"27","author":"Katri","year":"2019","journal-title":"Osteoarth. Cartil."},{"key":"B126","doi-asserted-by":"publisher","first-page":"394","DOI":"10.3390\/jcm15010394","article-title":"Increasing obesity rates worldwide from 1976 to 2016: the obesity Epidemic","volume":"15","author":"Keller","year":"2026","journal-title":"J. Clin. Med."},{"key":"B127","doi-asserted-by":"publisher","first-page":"1467","DOI":"10.1038\/s12276-025-01497-y","article-title":"Structural insights into GPCR signaling activated by peptide ligands: from molecular mechanism to therapeutic application","volume":"57","author":"Kim","year":"2025","journal-title":"Exp. Mol. Med."},{"key":"B128","doi-asserted-by":"publisher","first-page":"3416","DOI":"10.1021\/jacs.0c12043","article-title":"Glucagon like peptide 1 receptor agonists for targeted delivery of antisense oligonucleotides to pancreatic beta cell","volume":"143","author":"Knerr","year":"2021","journal-title":"J. Am. Chem. Soc."},{"key":"B129","doi-asserted-by":"publisher","first-page":"101533","DOI":"10.1016\/j.molmet.2022.101533","article-title":"Next generation GLP-1\/GIP\/glucagon triple agonists normalize body weight in Obese mice","volume":"63","author":"Knerr","year":"2022","journal-title":"Mol. Metab."},{"key":"B130","doi-asserted-by":"publisher","first-page":"155","DOI":"10.3389\/fendo.2019.00155","article-title":"The discovery and development of liraglutide and semaglutide","volume":"10","author":"Knudsen","year":"2019","journal-title":"Front. Endocrinol."},{"key":"B131","doi-asserted-by":"publisher","first-page":"1125","DOI":"10.1021\/acsmedchemlett.2c00161","article-title":"S-Protected cysteine sulfoxide-enabled tryptophan-selective modification with application to peptide lipidation","volume":"13","author":"Kobayashi","year":"2022","journal-title":"ACS Med. Chem. Lett."},{"key":"B132","doi-asserted-by":"publisher","first-page":"546","DOI":"10.1053\/j.ajkd.2016.09.027","article-title":"Kidney involvement in systemic calcitonin amyloidosis associated with medullary thyroid carcinoma","volume":"69","author":"Koopman","year":"2017","journal-title":"Am. J. Kidney Dis."},{"key":"B133","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1016\/j.str.2020.02.004","article-title":"A structural understanding of class B GPCR selectivity and activation revealed","volume":"28","author":"Krumm","year":"2020","journal-title":"Structure"},{"key":"B134","doi-asserted-by":"publisher","first-page":"11183","DOI":"10.1021\/acs.jmedchem.1c00565","article-title":"Development of cagrilintide, a long-acting amylin analogue","volume":"64","author":"Kruse","year":"2021","journal-title":"J. Med. Chem."},{"key":"B135","doi-asserted-by":"publisher","first-page":"725","DOI":"10.1042\/bj3120725","article-title":"Albumin binding of insulins acylated with fatty acids: characterization of the ligand-protein interaction and correlation between binding affinity and timing of the insulin effect in vivo","volume":"312","author":"Kurtzhals","year":"1995","journal-title":"Biochem. J."},{"key":"B136","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1038\/s41573-022-00529-w","article-title":"Derivatization with fatty acids in peptide and protein drug discovery","volume":"22","author":"Kurtzhals","year":"2023","journal-title":"Nat. Rev. Drug Discov."},{"key":"B137","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1186\/s40824-023-00421-7","article-title":"Design of chimeric GLP-1A using oligomeric bile acids to utilize transporter-mediated endocytosis for oral delivery","volume":"27","author":"Kweon","year":"2023","journal-title":"Biomater. Res."},{"key":"B138","doi-asserted-by":"publisher","first-page":"2700","DOI":"10.1016\/j.bmc.2017.06.052","article-title":"Therapeutic peptides: historical perspectives, current development trends, and future directions","volume":"26","author":"Lau","year":"2018","journal-title":"Bioorg. Med. Chem."},{"key":"B139","doi-asserted-by":"publisher","first-page":"7370","DOI":"10.1021\/acs.jmedchem.5b00726","article-title":"Discovery of the once-weekly glucagon-like Peptide-1 (GLP-1) analogue semaglutide","volume":"58","author":"Lau","year":"2015","journal-title":"J. Med. Chem."},{"key":"B140","doi-asserted-by":"publisher","first-page":"2160","DOI":"10.1016\/s0140-6736(21)01751-7","article-title":"Once-weekly cagrilintide for weight management in people with overweight and obesity: a multicentre, randomised, double-blind, placebo-controlled and active-controlled, dose-finding phase 2 trial","volume":"398","author":"Lau","year":"2021","journal-title":"Lancet"},{"key":"B141","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1016\/j.phrs.2016.12.006","article-title":"Molecular insights into allosteric modulation of class C G protein-coupled receptors","volume":"116","author":"Leach","year":"2017","journal-title":"Pharmacol. Res."},{"key":"B142","doi-asserted-by":"publisher","first-page":"9660","DOI":"10.1021\/acs.jmedchem.0c00740","article-title":"Engineering of a potent, long-acting NPY2R agonist for combination with a GLP-1R agonist as a multi-hormonal treatment for obesity","volume":"63","author":"Lear","year":"2020","journal-title":"J. Med. Chem."},{"key":"B143","doi-asserted-by":"publisher","first-page":"885","DOI":"10.1016\/j.jconrel.2024.07.008","article-title":"A novel chemically engineered multifunctional statin conjugate as self-assembled nanoparticles inhibiting bile acid transporters","volume":"372","author":"Lee","year":"2024","journal-title":"J. Controll. Release"},{"key":"B144","doi-asserted-by":"publisher","first-page":"480","DOI":"10.3390\/pharmaceutics17040480","article-title":"Preparation and therapeutic evaluation of engineered semaglutide and statin\u2013lipid conjugate-based nanoparticle","volume":"17","author":"Lee","year":"2025","journal-title":"Pharmaceutics"},{"key":"B145","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1517\/14728210902766813","article-title":"Emerging drugs for postmenopausal osteoporosis","volume":"14","author":"Lewiecki","year":"2009","journal-title":"Expert Opin. Emerg. Drugs"},{"key":"B146","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1038\/s41421-024-00700-0","article-title":"Structural insights into the triple agonism at GLP-1R, GIPR and GCGR manifested by retatrutide","volume":"10","author":"Li","year":"2024","journal-title":"Cell Discov."},{"key":"B147","doi-asserted-by":"publisher","first-page":"20711","DOI":"10.1021\/acsnano.5c02515","article-title":"Biomimetic liposomes for G-Protein-Coupled receptor 120 Exo\/endogenous coactivation to reprogram lipid metabolism in obesity-associated osteoarthritis","volume":"19","author":"Li","year":"2025","journal-title":"ACS Nano"},{"key":"B148","doi-asserted-by":"publisher","first-page":"433","DOI":"10.1016\/j.chembiol.2026.01.008","article-title":"Lysosome-targeting chimeras enable targeted protein degradation","volume":"33","author":"Li","year":"2026","journal-title":"Cell Chem. Biol."},{"key":"B149","doi-asserted-by":"publisher","first-page":"7438","DOI":"10.1021\/acs.jmedchem.2c00123","article-title":"Peptidomimetics: an overview of recent medicinal chemistry efforts toward the discovery of novel small molecule inhibitors","volume":"65","author":"Li Petri","year":"2022","journal-title":"J. Med. Chem."},{"key":"B150","doi-asserted-by":"publisher","first-page":"117320","DOI":"10.1016\/j.ejmech.2025.117320","article-title":"Rational design of dual-agonist peptides targeting GLP-1 and NPY2 receptors for regulating glucose homeostasis and body weight with minimal nausea and emesis","volume":"287","author":"Liu","year":"","journal-title":"E. J. Med. Chem."},{"key":"B151","doi-asserted-by":"publisher","first-page":"147553","DOI":"10.1016\/j.ijbiomac.2025.147553","article-title":"Development of a potent xenopus GLP-1-derived GLP-1\/GIP\/Y2 receptor tri-agonist for obesity and type 2 diabetes","volume":"328","author":"Liu","year":"","journal-title":"Int. J. Biol. Macromol."},{"key":"B152","doi-asserted-by":"publisher","first-page":"25689","DOI":"10.1021\/acs.jmedchem.5c02276","article-title":"Overcoming challenges in the metabolism of peptide therapeutics: strategies and case studies for clinical success","volume":"68","author":"Ma","year":"2025","journal-title":"J. Med. Chem."},{"key":"B153","doi-asserted-by":"publisher","first-page":"6126","DOI":"10.1021\/jm070861j","article-title":"Structure\u2212activity and protraction relationship of long-acting glucagon-like Peptide-1 derivatives: importance of fatty acid length, polarity, and bulkiness","volume":"50","author":"Madsen","year":"2007","journal-title":"J. Med. Chem."},{"key":"B154","doi-asserted-by":"publisher","DOI":"10.1101\/2025.01.13.632834","article-title":"Binding kinetics, bias, receptor internalization and effects on insulin secretion in vitro and in vivo of a novel GLP-1R\/GIPR dual agonist, HISHS-2001","author":"Manchanda","year":"2025","journal-title":"bioRxiv"},{"key":"B155","doi-asserted-by":"publisher","first-page":"1119","DOI":"10.1002\/jcp.30600","article-title":"Islet amyloid toxicity: from genesis to counteracting mechanisms","volume":"237","author":"Marmentini","year":"2022","journal-title":"J. Cell. Physiol."},{"key":"B156","doi-asserted-by":"publisher","first-page":"1650","DOI":"10.1021\/acsptsci.4c00173","article-title":"GLP-1 analogue-loaded glucose-responsive nanoparticles as allies of stem cell therapies for the treatment of type I diabetes","volume":"7","author":"Marques","year":"2024","journal-title":"ACS Pharmacol. Transl. Sci."},{"key":"B157","doi-asserted-by":"publisher","first-page":"1834","DOI":"10.1056\/NEJMoa1607141","article-title":"Semaglutide and cardiovascular outcomes in patients with type 2 diabetes","volume":"375","author":"Marso","year":"2016","journal-title":"N. E. J. Med."},{"key":"B158","doi-asserted-by":"publisher","first-page":"176215","DOI":"10.1016\/j.ejphar.2023.176215","article-title":"OXM-104, a potential candidate for the treatment of obesity, NASH and type 2 diabetes","volume":"962","author":"Melander","year":"2024","journal-title":"E. J. Pharmacol."},{"key":"B159","doi-asserted-by":"publisher","first-page":"1127","DOI":"10.1021\/acs.jmedchem.0c01783","article-title":"Design and evaluation of peptide dual-agonists of GLP-1 and NPY2 receptors for glucoregulation and weight loss with mitigated nausea and emesis","volume":"64","author":"Milliken","year":"2021","journal-title":"J. Med. Chem."},{"key":"B160","doi-asserted-by":"publisher","first-page":"738","DOI":"10.1038\/nm727","article-title":"Inhibition of gastric inhibitory polypeptide signaling prevents obesity","volume":"8","author":"Miyawaki","year":"2002","journal-title":"Nat. Med."},{"key":"B161","doi-asserted-by":"publisher","first-page":"4060","DOI":"10.3390\/ijms22084060","article-title":"Ligand-receptor interactions and machine learning in GCGR and GLP-1R drug discovery","volume":"22","author":"Mizera","year":"2021","journal-title":"Int. J. Mol. Sci."},{"key":"B162","doi-asserted-by":"publisher","first-page":"e12","DOI":"10.1016\/j.atherosclerosis.2021.06.039","article-title":"Concomitant glucose-dependent insulinotropic receptor (GIPR) and glucagon-like peptide-1 receptor (GLP1R) agonism stimulates TG-rich lipoprotein metabolism and attenuates atherosclerosis development","volume":"331","author":"Modder","year":"2021","journal-title":"Atherosclerosis"},{"key":"B163","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1186\/s13075-024-03361-2","article-title":"The dual amylin and calcitonin receptor agonist KBP-336 elicits a unique combination of weight loss, antinociception and bone protection \u2013 a novel disease-modifying osteoarthritis drug","volume":"26","author":"Mohamed","year":"2024","journal-title":"Arthritis Res. Ther."},{"key":"B164","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1007\/s10059-010-0100-5","article-title":"Tyr1 and Ile7 of glucose-dependent insulinotropic polypeptide (GIP) confer differential ligand selectivity toward GIP and glucagon-like peptide-1 receptors","volume":"30","author":"Moon","year":"2010","journal-title":"Mol. Cells"},{"key":"B165","doi-asserted-by":"publisher","first-page":"e68559","DOI":"10.1371\/journal.pone.0068559","article-title":"Molecular insight into the steric shielding effect of PEG on the conjugated staphylokinase: biochemical characterization and molecular dynamics simulation","volume":"8","author":"Mu","year":"2013","journal-title":"PLOS ONE"},{"key":"B166","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1210\/clinem\/dgad532","article-title":"Tirzepatide immunogenicity on pharmacokinetics, efficacy, and safety: analysis of data from phase 3 studies","volume":"109","author":"Mullins","year":"2024","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"B167","doi-asserted-by":"publisher","first-page":"e240046","DOI":"10.1530\/JOE-24-0046","article-title":"GLP-1 receptor agonist-based therapies and cardiovascular risk: a review of mechanisms","volume":"263","author":"Mullur","year":"2024","journal-title":"J. Endocrinol."},{"key":"B168","doi-asserted-by":"publisher","first-page":"2332","DOI":"10.2337\/db13-1563","article-title":"Chronic reduction of GIP secretion alleviates obesity and insulin resistance under high-fat diet conditions","volume":"63","author":"Nasteska","year":"2014","journal-title":"Diabetes"},{"key":"B169","doi-asserted-by":"publisher","first-page":"e24225","DOI":"10.1002\/pep2.24225","article-title":"Surfactant-modified parathyroid hormone fragments with high potency and prolonged action: structure-Informed design using glycolipid surfactant conjugation","volume":"113","author":"Nestor","year":"2021","journal-title":"Pept. Sci."},{"key":"B170","doi-asserted-by":"publisher","first-page":"e24221","DOI":"10.1002\/pep2.24221","article-title":"Design and characterization of a surfactant-conjugated, long-acting, balanced GLP-1\/glucagon receptor dual agonist","volume":"113","author":"Nestor","year":"2021","journal-title":"Pept. Sci."},{"key":"B171","doi-asserted-by":"publisher","first-page":"117496","DOI":"10.1016\/j.biopha.2024.117496","article-title":"Stapled peptides as potential therapeutics for diabetes and other metabolic diseases","volume":"180","author":"Nielipi\u0144ska","year":"2024","journal-title":"Biomed. Pharmacother."},{"key":"B172","doi-asserted-by":"publisher","first-page":"11814","DOI":"10.1021\/acs.jmedchem.4c00417","article-title":"Machine-learning-guided peptide drug discovery: development of GLP-1 receptor agonists with improved drug properties","volume":"67","author":"Nielsen","year":"2024","journal-title":"J. Med. Chem."},{"key":"B173","doi-asserted-by":"publisher","first-page":"103801","DOI":"10.1016\/j.eclinm.2026.103801","article-title":"Dapiglutide, a dual GLP-1 and GLP-2 receptor agonist, for obesity: a randomised, double-blind, placebo-controlled parallel-group, proof-of-concept trial","volume":"93","author":"Nielsen","year":"2026","journal-title":"eClinicalMedicine"},{"key":"B174","doi-asserted-by":"publisher","first-page":"e202401066","DOI":"10.1002\/cbic.202401066","article-title":"Conjugation of human N-Glycans improves the drug properties of existing peptides and proteins","volume":"26","author":"Nishiuchi","year":"2025","journal-title":"Chem. Bio. Chem."},{"key":"B175","doi-asserted-by":"publisher","first-page":"302","DOI":"10.1038\/ng.1086","article-title":"Common variants at CDKAL1 and KLF9 are associated with body mass index in East Asian populations","volume":"44","author":"Okada","year":"2012","journal-title":"Nat. Genet."},{"key":"B176","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1080\/17460441.2025.2601113","article-title":"Advancing obesity treatments through innovations in the design and manufacturing of therapeutic peptides","volume":"21","author":"\u00d8stergaard","year":"2026","journal-title":"Expert Opin. Drug Discov."},{"key":"B177","doi-asserted-by":"publisher","first-page":"8268","DOI":"10.1002\/anie.202016464","article-title":"The design of a GLP-1\/PYY dual acting agonist","volume":"60","author":"\u00d8stergaard","year":"2021","journal-title":"Angew. Chem. Int. Ed."},{"key":"B178","volume-title":"Palatin Initiates Phase 2 Clinical Study of Bremelanotide for the Treatment of Obesity","year":"2024"},{"key":"B179","doi-asserted-by":"publisher","first-page":"114330","DOI":"10.1016\/j.ejmech.2022.114330","article-title":"Design, synthesis and preclinical evaluation of bio-conjugated amylinomimetic peptides as long-acting amylin receptor agonists","volume":"236","author":"Patch","year":"2022","journal-title":"E. J. Med. Chem."},{"key":"B180","doi-asserted-by":"publisher","first-page":"1166","DOI":"10.1021\/acsmedchemlett.9b00182","article-title":"Design of a long-acting and selective MEG-fatty acid stapled prolactin-releasing peptide analog","volume":"10","author":"Pflimlin","year":"2019","journal-title":"ACS Med. Chem. Lett."},{"key":"B181","doi-asserted-by":"publisher","first-page":"382","DOI":"10.1021\/acs.jmedchem.9b01862","article-title":"Engineering a potent, long-acting, and periphery-restricted oxytocin receptor agonist with anorexigenic and body weight reducing effects","volume":"63","author":"Pflimlin","year":"2020","journal-title":"J. Med. Chem."},{"key":"B182","doi-asserted-by":"publisher","first-page":"101242","DOI":"10.1016\/j.molmet.2021.101242","article-title":"Partial agonism improves the anti-hyperglycaemic efficacy of an oxyntomodulin-derived GLP-1R\/GCGR co-agonist","volume":"51","author":"Pickford","year":"2021","journal-title":"Mol. Metab."},{"key":"B183","doi-asserted-by":"publisher","first-page":"1301017","DOI":"10.3389\/fendo.2023.1301017","article-title":"G protein-coupled receptors and obesity","volume":"14","author":"Pocai","year":"2023","journal-title":"Front. Endocrinol. (Lausanne)"},{"key":"B184","doi-asserted-by":"publisher","first-page":"1369","DOI":"10.1007\/s11095-021-03077-x","article-title":"Rational development of stable PYY(3-36) peptide Y(2) receptor agonists","volume":"38","author":"Poulsen","year":"2021","journal-title":"Pharm. Res."},{"key":"B185","doi-asserted-by":"publisher","first-page":"e51352","DOI":"10.7759\/cureus.51352","article-title":"Glucagon-like Peptide-1 receptor agonists in the treatment of idiopathic inflammatory myopathy: from mechanisms of action to clinical applications","volume":"15","author":"Rajagopal","year":"2023","journal-title":"Cureus"},{"key":"B186","doi-asserted-by":"publisher","first-page":"844","DOI":"10.1016\/j.jacbts.2018.09.004","article-title":"The GLP-1 analogs liraglutide and semaglutide reduce atherosclerosis in ApoE\u2212\/\u2212 and LDLr\u2212\/\u2212 mice by a mechanism that includes inflammatory pathways","volume":"3","author":"Rakipovski","year":"2018","journal-title":"JACC Basic Transl. Sci."},{"key":"B187","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1016\/j.bmcl.2015.12.024","article-title":"Biased agonism: an emerging paradigm in GPCR drug discovery","volume":"26","author":"Rankovic","year":"2016","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"B188","article-title":"Biochemistry, G protein coupled receptors","volume-title":"Statpearls. Treasure Island (FL): Statpearls Publishing Copyright \u00a9 2026","author":"Rehman","year":"2026"},{"key":"B189","doi-asserted-by":"publisher","first-page":"30","DOI":"10.3390\/chemosensors14020030","article-title":"Bioactive peptides from natural sources: biological functions, therapeutic potential and applications","volume":"14","author":"Rodr\u00edguez-Cabello","year":"2026","journal-title":"Chemosensors"},{"key":"B190","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1016\/s0140-6736(26)01022-6","article-title":"Cagrilintide-semaglutide (CagriSema) as an add-on to basal insulin in adults with type 2 diabetes (REIMAGINE 3): a randomised, double-blind, placebo-controlled, multicentre, phase 3 study","volume":"408","author":"Rosenstock","year":"2026","journal-title":"Lancet"},{"key":"B191","doi-asserted-by":"publisher","first-page":"101118","DOI":"10.1016\/j.molmet.2020.101118","article-title":"Behavioural and neurochemical mechanisms underpinning the feeding-suppressive effect of GLP-1\/CCK combinatorial therapy","volume":"43","author":"Roth","year":"2021","journal-title":"Mol. Metab."},{"key":"B192","doi-asserted-by":"publisher","first-page":"399","DOI":"10.3390\/ph18030399","article-title":"Semaglutide as a GLP-1 agonist: a breakthrough in obesity treatment","volume":"18","author":"Salvador","year":"2025","journal-title":"Pharm. (Basel)"},{"key":"B193","doi-asserted-by":"publisher","first-page":"2146","DOI":"10.1007\/s13346-024-01729-0","article-title":"Design of self-emulsifying oral delivery systems for semaglutide: reverse micelles versus hydrophobic ion pairs","volume":"15","author":"Sandmeier","year":"2025","journal-title":"Drug Deliv. Transl. Res."},{"key":"B194","doi-asserted-by":"publisher","first-page":"2425","DOI":"10.1021\/acs.accounts.0c00482","article-title":"Sulfono-\u03b3-AApeptides as helical mimetics: crystal structures and applications","volume":"3","author":"Sang","year":"","journal-title":"Acc. Chem. Res."},{"key":"B195","doi-asserted-by":"publisher","first-page":"eaaz4988","DOI":"10.1126\/sciadv.aaz4988","article-title":"The activity of sulfono-\u03b3-AApeptide helical foldamers that mimic GLP-1","volume":"6","author":"Sang","year":"","journal-title":"Sci. Adv."},{"key":"B196","doi-asserted-by":"publisher","first-page":"13893","DOI":"10.1021\/acs.jmedchem.1c01289","article-title":"\u03b1\/Sulfono-\u03b3-AApeptide hybrid analogues of glucagon with enhanced stability and prolonged in vivo activity","volume":"64","author":"Sang","year":"2021","journal-title":"J. Med. Chem."},{"key":"B197","doi-asserted-by":"publisher","first-page":"12","DOI":"10.3390\/molecules30010012","article-title":"Design, structure\u2013activity relationships, and computational modeling studies of a series of \u03b1-Helix biased, ultra-short glucagon-like Peptide-1 receptor agonists","volume":"30","author":"Sawyer","year":"2025","journal-title":"Molecules"},{"key":"B198","doi-asserted-by":"publisher","first-page":"818","DOI":"10.1016\/s2213-8587(25)00219-0","article-title":"Ecnoglutide, a biased GLP-1 receptor agonist as a potential new player for type 2 diabetes management?","volume":"13","author":"Scheen","year":"2025","journal-title":"Lancet Diabetes Endocrinol."},{"key":"B199","doi-asserted-by":"publisher","first-page":"5575","DOI":"10.1007\/s00210-025-04548-3","article-title":"Do GPCRs constitute the target of 30% of newly approved drugs in Germany?","volume":"399","author":"Schr\u00f6er","year":"2025","journal-title":"Schmiedeb. Arch. Pharmacol."},{"key":"B200","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1016\/j.rinphs.2012.09.001","article-title":"Enzymatic mono-pegylation of glucagon-like peptide 1 towards long lasting treatment of type 2 diabetes","volume":"2","author":"Selis","year":"2012","journal-title":"Results Pharma Sci."},{"key":"B201","doi-asserted-by":"publisher","first-page":"2622","DOI":"10.2337\/db07-0225","article-title":"The role of melanocortin 3 receptor gene in childhood obesity","volume":"56","author":"Seng Lee","year":"2007","journal-title":"Diabetes"},{"key":"B202","doi-asserted-by":"publisher","first-page":"1648","DOI":"10.1016\/j.apsb.2022.10.014","article-title":"\u03b1\/Sulfono-\u03b3-AA peptide hybrids agonist of GLP-1R with prolonged action both in vitro and in vivo","volume":"13","author":"Shi","year":"2023","journal-title":"Acta Pharm. Sin. B"},{"key":"B203","doi-asserted-by":"publisher","first-page":"e0264974","DOI":"10.1371\/journal.pone.0264974","article-title":"Preclinical evaluation of a protracted GLP-1\/glucagon receptor co-agonist: translational difficulties and pitfalls","volume":"17","author":"Simonsen","year":"2022","journal-title":"PLOS ONE"},{"key":"B204","doi-asserted-by":"publisher","first-page":"106022","DOI":"10.1016\/j.appet.2022.106022","article-title":"A comparative transcriptomic analysis of glucagon-like peptide-1 receptor- and glucose-dependent insulinotropic polypeptide receptor-expressing cells in the hypothalamus","volume":"174","author":"Smith","year":"2022","journal-title":"Appetite"},{"key":"B205","doi-asserted-by":"publisher","first-page":"312","DOI":"10.1038\/nature22378","article-title":"Human GLP-1 receptor transmembrane domain structure in complex with allosteric modulators","volume":"546","author":"Song","year":"2017","journal-title":"Nature"},{"key":"B206","doi-asserted-by":"publisher","first-page":"1084","DOI":"10.1111\/dom.14672","article-title":"Effect of bremelanotide on body weight of obese women: data from two phase 1 randomized controlled trials","volume":"24","author":"Spana","year":"2022","journal-title":"Diabetes Obes. Metab."},{"key":"B207","doi-asserted-by":"publisher","first-page":"1570","DOI":"10.1111\/j.1471-4159.2009.06085.x","article-title":"Olfactory receptors: g protein-coupled receptors and beyond","volume":"109","author":"Spehr","year":"2009","journal-title":"J. Neurochem."},{"key":"B208","doi-asserted-by":"publisher","first-page":"4661","DOI":"10.2147\/dmso.S579897","article-title":"Metabolic disorders and complications","volume":"18","author":"Sull","year":"2025","journal-title":"Diabetes Metab. Syndr. Obes."},{"key":"B209","doi-asserted-by":"publisher","first-page":"740","DOI":"10.3390\/ph15060740","article-title":"Rational design by structural biology of industrializable, long-acting antihyperglycemic GLP-1 receptor agonists","volume":"15","author":"Sun","year":"","journal-title":"Pharm. (Basel)"},{"key":"B210","doi-asserted-by":"publisher","first-page":"112722","DOI":"10.1016\/j.biopha.2022.112722","article-title":"Small-molecule albumin ligand modification to enhance the anti-diabetic ability of GLP-1 derivatives","volume":"148","author":"Sun","year":"","journal-title":"Biomed. Pharmacother."},{"key":"B211","doi-asserted-by":"publisher","first-page":"171203","DOI":"10.1016\/j.peptides.2024.171203","article-title":"Identification and utility exploration of a highly potent and long-acting bullfrog GLP-1 analogue in GLP-1 and amylin combination therapy","volume":"177","author":"Sun","year":"2024","journal-title":"Peptides"},{"key":"B212","doi-asserted-by":"publisher","first-page":"e01043","DOI":"10.1002\/prp2.1043","article-title":"Selective somatostatin receptor 5 inhibition improves hepatic insulin sensitivity","volume":"11","author":"Tamura","year":"2023","journal-title":"Pharmacol. Res. Perspect."},{"key":"B213","doi-asserted-by":"publisher","first-page":"173650","DOI":"10.1016\/j.ejphar.2020.173650","article-title":"Albumin-binding domain extends half-life of glucagon-like peptide-1","volume":"890","author":"Tan","year":"2021","journal-title":"E. J. Pharmacol."},{"key":"B214","doi-asserted-by":"publisher","first-page":"12089","DOI":"10.1039\/D0RA01002B","article-title":"Discovery of lixisenatide analogues as long-acting hypoglycemic agents using novel peptide half-life extension technology based on mycophenolic acid","volume":"10","author":"Tang","year":"2020","journal-title":"RSC Adv."},{"key":"B215","doi-asserted-by":"publisher","first-page":"5458","DOI":"10.1002\/chem.201504936","article-title":"\u03b3-AApeptides as a new class of peptidomimetics","volume":"22","author":"Teng","year":"2016","journal-title":"Chemistry"},{"key":"B216","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1016\/j.ijbiomac.2021.01.207","article-title":"Molecular simulation of zwitterionic polypeptides on protecting glucagon-like peptide-1 (GLP-1)","volume":"174","author":"Teng","year":"2021","journal-title":"Int. J. Biol. Macromol."},{"key":"B217","doi-asserted-by":"publisher","first-page":"3479","DOI":"10.1021\/acs.jmedchem.1c00185","article-title":"Synthesis, optimization, and biological evaluation of corrinated conjugates of the GLP-1R agonist Exendin-4","volume":"64","author":"Tinsley","year":"2021","journal-title":"J. Med. Chem."},{"key":"B218","doi-asserted-by":"publisher","first-page":"1812","DOI":"10.1021\/acs.bioconjchem.0c00286","article-title":"Zwitterionic polymer conjugated glucagon-like Peptide-1 for prolonged glycemic control","volume":"31","author":"Tsao","year":"2020","journal-title":"Bioconjug. Chem."},{"key":"B219","doi-asserted-by":"publisher","first-page":"942","DOI":"10.4161\/psb.4.10.9530","article-title":"Signaling through G protein coupled receptors","volume":"4","author":"Tuteja","year":"2009","journal-title":"Plant Signal. Behav."},{"key":"B220","doi-asserted-by":"publisher","first-page":"723","DOI":"10.1074\/jbc.M109.033829","article-title":"Crystal structure of glucagon-like Peptide-1 in complex with the extracellular domain of the glucagon-like Peptide-1 receptor","volume":"285","author":"Underwood","year":"2010","journal-title":"J. Biol. Chem."},{"key":"B221","volume-title":"FDA Approves Treatment for Weight Management in Patients with Bardet-Biedl syndrome Aged 6 or Older","year":"2022"},{"key":"B222","doi-asserted-by":"publisher","first-page":"e194743","DOI":"10.1172\/jci194743","article-title":"GLP-1 receptor agonists and cancer: current clinical evidence and translational opportunities for preclinical research","volume":"135","author":"Valencia-Rinc\u00f3n","year":"2025","journal-title":"J. Clin. Invest."},{"key":"B223","doi-asserted-by":"publisher","first-page":"296","DOI":"10.1021\/acsptsci.0c00193","article-title":"GLP-1 Val8: a biased GLP-1R agonist with altered binding kinetics and impaired release of pancreatic hormones in rats","volume":"4","author":"van der Velden","year":"2021","journal-title":"ACS Pharmacol. Transl. Sci."},{"key":"B224","doi-asserted-by":"publisher","first-page":"14547","DOI":"10.1073\/pnas.1902192116","article-title":"Crystal structure of jumping spider rhodopsin-1 as a light sensitive GPCR","volume":"116","author":"Varma","year":"2019","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"B225","doi-asserted-by":"publisher","first-page":"290","DOI":"10.1038\/s42255-023-00966-w","article-title":"A GIPR antagonist conjugated to GLP-1 analogues promotes weight loss with improved metabolic parameters in preclinical and phase 1 settings","volume":"6","author":"V\u00e9niant","year":"2024","journal-title":"Nat. Metab."},{"key":"B226","doi-asserted-by":"publisher","first-page":"482","DOI":"10.1038\/s41574-025-01125-9","article-title":"Amylin: emergent therapeutic opportunities in overweight, obesity and diabetes mellitus","volume":"21","author":"Walker","year":"2025","journal-title":"Nat. Rev. Endocrinol."},{"key":"B227","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1038\/s41392-022-00904-4","article-title":"Therapeutic peptides: current applications and future directions","volume":"7","author":"Wang","year":"","journal-title":"Signal Transduct. Target Ther."},{"key":"B228","doi-asserted-by":"publisher","first-page":"11759","DOI":"10.1021\/acs.jmedchem.2c00653","article-title":"Modifying a hydroxyl patch in glucagon-like peptide 1 produces biased agonists with unique signaling profiles","volume":"65","author":"Wang","year":"","journal-title":"J. Med. Chem."},{"key":"B229","doi-asserted-by":"publisher","first-page":"118266","DOI":"10.1016\/j.bmc.2025.118266","article-title":"Design, synthesis, and biological evaluation of long-acting glucagon-like peptide-1 (GLP-1) conjugates modified with dual fatty acids and a proline-alanine-serine (PAS) polypeptide","volume":"128","author":"Wang","year":"","journal-title":"Bioorg. Med. Chem."},{"key":"B230","doi-asserted-by":"publisher","first-page":"20765","DOI":"10.1021\/acs.jmedchem.5c02032","article-title":"Strategic design of triple GLP-1R\/GCGR\/GIPR agonists with varied receptor potency: achieving comparable glycemic and weight reduction effects","volume":"68","author":"Wang","year":"","journal-title":"J. Med. Chem."},{"key":"B231","doi-asserted-by":"publisher","first-page":"e07044","DOI":"10.1002\/advs.202507044","article-title":"AI-Driven de novo Design of Ultra Long-Acting GLP-1 Receptor Agonists","volume":"12","author":"Wei","year":"2025","journal-title":"Adv. Sci."},{"key":"B232","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1016\/B978-0-323-85732-1.00011-6","article-title":"Chapter 28 - glucagon and the metabolic syndrome","volume-title":"Metabolic Syndrome","author":"Welch","year":"2024"},{"key":"B233","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.140532","article-title":"Tirzepatide is an imbalanced and biased dual GIP and GLP-1 receptor agonist","volume":"5","author":"Willard","year":"2020","journal-title":"JCI Insight"},{"key":"B234","doi-asserted-by":"publisher","first-page":"5","DOI":"10.3389\/fbinf.2025.1687617","article-title":"Machine learning-guided optimization of triple agonist peptide therapeutics for metabolic disease","volume":"5","author":"Wong","year":"","journal-title":"Front. Bioinforma."},{"key":"B235","doi-asserted-by":"publisher","first-page":"6178","DOI":"10.1021\/acs.jmedchem.4c02153","article-title":"2FA-Platform generates dual fatty acid-conjugated GLP-1 receptor agonist TE-8105 with enhanced diabetes, obesity, and NASH efficacy compared to semaglutide","volume":"68","author":"Wong","year":"","journal-title":"J. Med. Chem."},{"key":"B236","doi-asserted-by":"publisher","first-page":"1632","DOI":"10.1016\/j.cell.2016.05.023","article-title":"The extracellular surface of the GLP-1 receptor is a molecular trigger for biased agonism","volume":"165","author":"Wootten","year":"2016","journal-title":"Cell"},{"key":"B237","doi-asserted-by":"publisher","first-page":"9348","DOI":"10.1021\/acs.jmedchem.6c00032","article-title":"Discovery of AMG 133, a glucose-dependent insulinotropic polypeptide receptor antagonist and glucagon-like peptide 1 receptor agonist antibody-drug conjugate for the treatment of obesity","volume":"69","author":"Wu","year":"2026","journal-title":"J. Med. Chem."},{"key":"B238","doi-asserted-by":"publisher","first-page":"2390","DOI":"10.2337\/diabetes.54.8.2390","article-title":"Subcutaneous oxyntomodulin reduces body weight in overweight and obese subjects: a double-blind, randomized, controlled trial","volume":"54","author":"Wynne","year":"2005","journal-title":"Diabetes"},{"key":"B239","doi-asserted-by":"publisher","first-page":"1790","DOI":"10.1021\/acssynbio.5c00132","article-title":"Design and biosynthesis of ornithine 8-containing semaglutide variants with a click chemistry-modifiable position 26","volume":"14","author":"Xu","year":"2025","journal-title":"ACS Synth. Biol."},{"key":"B240","doi-asserted-by":"publisher","first-page":"171073","DOI":"10.1016\/j.peptides.2023.171073","article-title":"Engineering a potent and long-acting GLP-1\/Y2 receptor dual agonist as a multi-agonist therapy for diabetes and obesity","volume":"169","author":"Xu","year":"2023","journal-title":"Peptides"},{"key":"B241","doi-asserted-by":"publisher","first-page":"11425","DOI":"10.1021\/acs.jcim.5c00884","article-title":"State-specific peptide design targeting G protein-coupled receptors","volume":"65","author":"Xue","year":"2025","journal-title":"J. Chem. Inf. Model."},{"key":"B242","doi-asserted-by":"publisher","first-page":"2046","DOI":"10.1073\/pnas.0507471103","article-title":"Design of a mimic of nonamyloidogenic and bioactive human islet amyloid polypeptide (IAPP) as nanomolar affinity inhibitor of IAPP cytotoxic fibrillogenesis","volume":"103","author":"Yan","year":"2006","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"B243","doi-asserted-by":"publisher","first-page":"1167","DOI":"10.1021\/acs.bioconjchem.0c00093","article-title":"New generation oxyntomodulin peptides with improved pharmacokinetic profiles exhibit weight reducing and anti-steatotic properties in mice","volume":"31","author":"Yang","year":"2020","journal-title":"Bioconjugate Chem."},{"key":"B244","doi-asserted-by":"publisher","first-page":"14201","DOI":"10.1021\/acs.jmedchem.2c01385","article-title":"Design of xenopus GLP-1-Based long-acting dual GLP-1\/Y2 receptor agonists","volume":"65","author":"Yang","year":"","journal-title":"J. Med. Chem."},{"key":"B245","doi-asserted-by":"publisher","first-page":"114214","DOI":"10.1016\/j.ejmech.2022.114214","article-title":"Peptide-based long-acting co-agonists of GLP-1 and cholecystokinin 1 receptors as novel anti-diabesity agents","volume":"233","author":"Yang","year":"","journal-title":"E. J. Med. Chem."},{"key":"B246","doi-asserted-by":"publisher","first-page":"1249","DOI":"10.1021\/acschembio.2c00175","article-title":"Design of potent and proteolytically stable biaryl-stapled GLP-1R\/GIPR peptide dual agonists","volume":"17","author":"Yang","year":"","journal-title":"ACS Chem. Biol."},{"key":"B247","doi-asserted-by":"publisher","first-page":"2000073","DOI":"10.1002\/adtp.202000073","article-title":"Recombinant fusion of glucagon-like Peptide-1 and an albumin binding domain provides glycemic control for a week in diabetic mice","volume":"3","author":"Yousefpour","year":"2020","journal-title":"Adv. Ther."},{"key":"B248","doi-asserted-by":"publisher","first-page":"e61477","DOI":"10.1371\/journal.pone.0061477","article-title":"Treatment of obesity and diabetes using oxytocin or analogs in patients and mouse models","volume":"8","author":"Zhang","year":"2013","journal-title":"PLoS One"},{"key":"B249","doi-asserted-by":"publisher","first-page":"116291","DOI":"10.1016\/j.bmc.2021.116291","article-title":"Design, synthesis and biological evaluation of double fatty chain-modified glucagon-like peptide-1 conjugates","volume":"44","author":"Zhang","year":"","journal-title":"Bioorg. Med. Chem."},{"key":"B250","doi-asserted-by":"publisher","first-page":"833","DOI":"10.1016\/j.cmet.2021.01.015","article-title":"The glucose-dependent insulinotropic polypeptide (GIP) regulates body weight and food intake via CNS-GIPR signaling","volume":"33","author":"Zhang","year":"","journal-title":"Cell Metab."},{"key":"B251","doi-asserted-by":"publisher","first-page":"109374","DOI":"10.1016\/j.celrep.2021.109374","article-title":"Structure and dynamics of semaglutide- and taspoglutide-bound GLP-1R-Gs complexes","volume":"36","author":"Zhang","year":"","journal-title":"Cell Rep."},{"key":"B252","doi-asserted-by":"publisher","first-page":"108599","DOI":"10.1016\/j.neuropharm.2021.108599","article-title":"A novel dual agonist of glucagon-like peptide-1 receptors and neuropeptide Y2 receptors attenuates fentanyl taking and seeking in male rats","volume":"192","author":"Zhang","year":"","journal-title":"Neuropharmacology"},{"key":"B253","doi-asserted-by":"publisher","first-page":"170948","DOI":"10.1016\/j.peptides.2023.170948","article-title":"Discovery of novel OXM-based glucagon-like peptide 1 (GLP-1)\/glucagon receptor dual agonists","volume":"161","author":"Zhang","year":"","journal-title":"Peptides"},{"key":"B254","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1016\/j.cmet.2023.01.001","article-title":"Activity-balanced GLP-1\/GDF15 dual agonist reduces body weight and metabolic disorder in mice and non-human primates","volume":"35","author":"Zhang","year":"","journal-title":"Cell Metab."},{"key":"B255","doi-asserted-by":"publisher","first-page":"e70251","DOI":"10.1111\/jcmm.70251","article-title":"Targeting the GDF15 signalling for obesity treatment: recent advances and emerging challenges","volume":"28","author":"Zhang","year":"2024","journal-title":"J. Cell. Mol. Med."},{"key":"B256","doi-asserted-by":"publisher","first-page":"693","DOI":"10.1021\/acs.bioconjchem.4c00169","article-title":"Customizable click biochemistry strategy for the design and preparation of glucagon-like Peptide-1 conjugates and coagonists","volume":"35","author":"Zheng","year":"2024","journal-title":"Bioconjugate Chem."},{"key":"B257","doi-asserted-by":"publisher","first-page":"24701","DOI":"10.1021\/acs.jmedchem.5c02893","article-title":"Engineering of an ultralong-acting and nonaggregating dual Amylin and calcitonin receptor agonist with durable efficacy in obesity and diabetes","volume":"68","author":"Zheng","year":"","journal-title":"J. Med. Chem."},{"key":"B258","doi-asserted-by":"publisher","first-page":"305","DOI":"10.3390\/medsci13040269","article-title":"Incretins and development of incretin-based therapeutics","volume":"69","author":"Zheng","year":"","journal-title":"Pept. Sci."},{"key":"B259","doi-asserted-by":"publisher","first-page":"4984","DOI":"10.1021\/acs.jmedchem.5c03845","article-title":"Discovery and preclinical evaluation of TPM003: a novel GLP-1\/GIP\/Glucagon triple hormone receptor agonist with robust efficacy in obesity and NASH","volume":"69","author":"Zheng","year":"2026","journal-title":"J. Med. Chem."},{"key":"B260","doi-asserted-by":"publisher","first-page":"170811","DOI":"10.1016\/j.peptides.2022.170811","article-title":"Discovery of once-weekly, peptide-based selective GLP-1 and cholecystokinin 2 receptors co-agonizts","volume":"153","author":"Zhou","year":"2022","journal-title":"Peptides"},{"key":"B261","doi-asserted-by":"publisher","first-page":"16578","DOI":"10.1021\/acs.jmedchem.5c01399","article-title":"Long-acting and stapled GLP-1R\/GIPR\/GCGR triple agonist for the treatment of obesity and atherosclerosis","volume":"68","author":"Zhou","year":"2025","journal-title":"J. Med. Chem."},{"key":"B262","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1021\/acs.bioconjchem.5c00558","article-title":"Development of a long-acting and stapled dual Amylin and calcitonin receptor agonist as monotherapy and combination with GLP-1R agonists for the treatment of obesity","volume":"37","author":"Zhou","year":"2026","journal-title":"Bioconjugate Chem."},{"key":"B263","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1038\/s41597-022-01287-5","article-title":"HORDB a comprehensive database of peptide hormones","volume":"9","author":"Zhu","year":"2022","journal-title":"Sci. Data"},{"key":"B264","doi-asserted-by":"publisher","first-page":"106908","DOI":"10.1016\/j.bioorg.2023.106908","article-title":"Conjugation with glucagon like peptide-1 enables targeted protein degradation","volume":"141","author":"Zhu","year":"2023","journal-title":"Bioorg. Chem."},{"key":"B265","doi-asserted-by":"publisher","first-page":"1101","DOI":"10.1002\/biof.2059","article-title":"Novel enzyme-resistant pancreatic polypeptide analogs evoke pancreatic beta-cell rest, enhance islet cell turnover, and inhibit food intake in mice","volume":"50","author":"Zhu","year":"2024","journal-title":"BioFactors"},{"key":"B266","doi-asserted-by":"publisher","first-page":"1420","DOI":"10.1038\/s41467-025-68165-7","article-title":"Efficacy and safety of cAMP signalling-biased GLP-1 analogue ecnoglutide monotherapy versus placebo in patients with type 2 diabetes (EECOH-1): a multi-centre, randomised, double-blind, placebo-controlled, phase 3 trial","volume":"17","author":"Zhu","year":"2026","journal-title":"Nat. Comm."},{"key":"B267","doi-asserted-by":"publisher","first-page":"101633","DOI":"10.1016\/j.molmet.2022.101633","article-title":"BI 456906: discovery and preclinical pharmacology of a novel GCGR\/GLP-1R dual agonist with robust anti-obesity efficacy","volume":"66","author":"Zimmermann","year":"2022","journal-title":"Mol. Metab."},{"key":"B268","doi-asserted-by":"publisher","first-page":"14907","DOI":"10.1021\/acs.jmedchem.5c01120","article-title":"Discovery of BGM1812, a novel dual Amylin and calcitonin receptor agonist for obesity treatment","volume":"68","author":"Zong","year":"2025","journal-title":"J. Med. Chem."}],"container-title":["Frontiers in Pharmacology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2026.1930768\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T08:35:57Z","timestamp":1789547757000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2026.1930768\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,16]]},"references-count":268,"alternative-id":["10.3389\/fphar.2026.1930768"],"URL":"https:\/\/doi.org\/10.3389\/fphar.2026.1930768","relation":{},"ISSN":["1663-9812"],"issn-type":[{"value":"1663-9812","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,16]]},"article-number":"1930768"}}